Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIPRIVAN vs SUPRENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Adults: 200 mg orally twice daily with meals.
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
95-99% bound, primarily to albumin.
Approximately 95-98% bound to plasma proteins, primarily albumin.
2-10 L/kg (large Vd indicating extensive tissue distribution).
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
Oral bioavailability is approximately 70-80%.
No adjustment required; propofol is not significantly renally eliminated.
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
Not recommended for patients under 18 years; safety and efficacy not established.
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIPRIVAN vs SUPRENZA, answered by our medical review team.
DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIPRIVAN and SUPRENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIPRIVAN and SUPRENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.